

Agonists in the Extended Conformation Stabilize the Active State of β -Adrenoceptors

Alexander V. Efimov^{1,a*}, Olga V. Meshcheryakova^{2,b}, and Alexey G. Ryazanov^{3,c}

¹*Institute of Protein Research, Russian Academy of Sciences,
142290 Pushchino, Moscow Region, Russia*

²*Institute of Biology of the Karelian Research Centre of the Russian Academy of Sciences,
185910 Petrozavodsk, Russia*

³*Department of Pharmacology, Rutgers Robert Wood Johnson Medical School,
Piscataway, 08854 New Jersey, USA*

^a*e-mail: efimov@protres.ru*

^b*e-mail: mesch@krc.karelia.ru*

^c*e-mail: ryazanag@rwjms.rutgers.edu*

Received March 21, 2022

Revised June 21, 2022

Accepted June 21, 2022

Abstract—In this study, we conducted a comparative analysis of the structure of agonists and antagonists of transmembrane (TM) β -adrenoceptors (β -ARs) and their interactions with the β -ARs and proposed the mechanism of receptor activation. A characteristic feature of agonist and antagonist molecules is the presence of a hydrophobic head (most often, one or two aromatic rings) and a tail with a positively charged amino group. All β -adrenergic agonists have two carbon atoms between the aromatic ring of the head and the nitrogen atom of the amino group. In antagonist molecules, this fragment can be either reduced or increased to four atoms due to the additional carbon and oxygen atoms. The agonist head, as a rule, has two H-bond donors or acceptors in the *para*- and *meta*-positions of the aromatic rings, while in the antagonist heads, these donors/acceptors are absent or located in other positions. Analysis of known three-dimensional structures of β -AR complexes with agonists showed that the agonist head forms two H-bonds with the TM5 helix, and the tail forms an ionic bond with the D3.32 residue of the TM3 helix and one or two H-bonds with the TM7 helix. The tail of the antagonist can form similar bonds, but the interaction between the head and the TM5 helix is much weaker. As a result of these interactions, the agonist molecule acquires an extended “strained string” conformation, in contrast to the antagonist molecule, which has a longer, bended, and flexible tail. The “strained string” of the agonist interacts with the TM6 helix (primarily with the W6.48 residue) and turns it, which leads to the opening of the G protein-binding site on the intracellular side of the receptor, while flexible and larger antagonist molecules do not have the same effect on the receptor.

DOI: 10.1134/S0006297922070057

Keywords: β -adrenoceptor, GPCR, agonist, antagonist, activation mechanism

INTRODUCTION

G protein-coupled receptors (GPCRs) constitute the largest family of cell membrane receptors that includes over 800 human proteins targeted by at least 30% of current medicines (see reviews [1, 2]). This might be the main reason why GPCRs have been extensively studied in several recent decades, resulting in the elucidation of many aspects of their biology, biochemistry, and pharma-

cology. Originally, the behavior of GPCRs was described in terms of a simple two-state model; however, there is growing body of evidence that GPCRs are not molecular switches, but rather molecular relays, i.e., dynamic proteins with multiple states between active and inactive conformations [4-8].

Recent crystallography data have provided the snapshots of both active and inactive functional states of GPCRs [9, 10]. GPCR structures solved so far share the same overall fold — a bundle of seven transmembrane (TM) α -helices with three extra- and three intracellular

* To whom correspondence should be addressed.

loops. The extracellular interface is responsible for the ligand binding, while the intracellular portion interacts with G proteins, β -arrestins, and other downstream effectors. Analysis of known GPCR structures indicates that receptor activation is associated with subtle changes in the extracellular portion of the protein and extensive rearrangement of the TM helices on the cytoplasmic side [11, 12]. Agonist binding at the GPCR extracellular interface results in the opening of the intracellular part for the G protein binding, which promotes G protein activation (GDP release) and initiates the signaling cascade.

The progress in membrane protein crystallography and related techniques in the past decade [7, 13] has allowed to elucidate many aspects of GPCR structure, activation, and physiology; however, some details of ligand recognition and receptor activation remain poorly understood. One of the main aims of this study was comparative analysis of the structures of β -adrenoceptor (β -AR) ligands. Based on the results of this analysis, we proposed that agonist molecules adopt an extended (“strained string”) conformation and stabilize the active state of β -AR, in contrast to antagonist molecules, which have longer and flexible tail and fail to produce the same effect on the receptors.

MATERIALS AND METHODS

As the main research approaches in this study, we used stereochemical analysis of the known three-dimensional structures of β -AR complexes with the corresponding ligands and comparative analysis of the chemical structure of agonists and antagonists and their conformations in the complexes. For this, we created a database of such complexes that included 64 structures determined by crystallography so far and a database of β -AR sequences from the Swiss-Prot UniProt [14]. The atomic coordinates of the complexes were taken from the Protein Data Bank (PDB, URL: <https://www.rcsb.org>) [15]. The three-dimensional structures of the receptors and their ligands were analyzed using RasMol [16] and PyMOL Molecular Graphics System Version 1.4.1 Schrödinger, LLC. β -AR subtypes designated using the nomenclature recommended by the NC-IUPHAR Subcommittee on Adrenergic Receptors. Amino acid residues in β -ARs were designated according to the Ballesteros and Weinstein nomenclature [17]. Multiple sequence alignment was performed with the Clustal Omega program (1.2.4) included in the UniProt resource [14]. Images of ligand molecules were taken from the Drug Informational Portal, ChEBI, and ChemSpider.

RESULTS AND DISCUSSION

Comparative analysis of chemical structures of β -AR ligands. In terms of receptor activation (intrinsic effica-

cy), GPCR ligands can be categorized into four groups: (i and ii) full and partial agonists that produce the maximal or sub-maximal functional response, respectively; (iii) inverse agonists that decrease the basal receptor activity (activity in the absence of ligand); and (iv) neutral antagonists, that compete with other ligands for the orthosteric binding site, but their interaction with the receptor does not result in the G protein binding.

Table 1 shows chemical structures of β -AR agonists that have been co-crystallized with the receptor. A characteristic feature of these molecules is the presence of an aromatic head and a tail with a positively charged amine. The tail consists of ethanolamine core and various substituents connected to the amine group. Hydroxyl groups in the *para*- and *meta*-positions of the catechol moieties and in the *para*-position in aromatic rings of non-catechol agonists can form hydrogen bonds with the receptor helices.

Aromatic heterocyclic heads of non-catechol agonists can have other donors and acceptors of hydrogen bonds that might be involved in the binding with the receptor. Hence, GPCR agonists have two centers of polar interactions with the receptor (donors/acceptors of H-bonds of the head and donors/acceptors and positively charged amine of the tail). One may ask if the distance between these centers has any influence on the specificity of receptor–ligand interactions. As seen in Table 1, the length of the tail fragment between the N-atom and the aromatic ring is the same in all agonists and comprises three covalent bonds. In other words, the N-atom is separated by 2 carbons from the substituted benzene or other aromatic ring. Moreover, in all agonists with six-membered aromatic rings, the O-atoms of hydroxyls located in the *para*- and *meta*-positions and the N-atoms of the tail are separated by seven and six covalent bonds, respectively.

For comparison, Table 2 shows partial agonists, antagonists, and inverse agonists (referred to as β -blockers after Emtage et al. [28]). These compounds also have aromatic heads and tails with positively charged amine groups. However, compared to agonists, these ligands have either longer (Table 2) or shorter (e.g., doxepin and bretylium tosylate not shown here) tail fragments between the amine N-atom and the aromatic ring. In most cases, the N-atom of the amine group is separated from the aromatic ring by 4 atoms (often one of them is O). Moreover, antagonists and inverse agonists presented in Table 2 do not contain donors or acceptors of H-bonds in the *para*-position of the aromatic head or even lack them at all. Note that the NH-groups of cyanopindolol and carazolol are located in the *meta*-position relative to the tail. Another feature of β -blockers is that they typically have larger heads consisting of two and three rings as compared to the agonists.

Two centers of polar interactions between β -ARs and their agonists. The orthosteric binding pocket of β -ARs is located within the TM region and is primarily composed of the extracellular fragments of the TM helices 3, 5, 6,

Table 1. β -AR agonists that have been co-crystallized with the receptor







β -AR agonist	Structure	β -AR, organism	PDB ID	Resolution, Å	References
Carmoterol		β_1 -AR, turkey	2Y02	2.60	[18]
Dobutamine		β_1 -AR, turkey	2Y00	2.50	[18]
			6H7L	2.70	[19]
Epinephrine		β_1 -AR, human	4LDO	3.20	[20]
		β_2 -AR, human	7BTS	3.13	[21]
Formoterol		β_1 -AR, turkey	6IBL 6TKO	2.70 3.30	[22]
		β_2 -AR, human	7BZ2	3.82	[23]
Hydroxybenzyl-isoproterenol		β_2 -AR, human	4LDL	3.10	[20]
Isoprenaline		β_1 -AR, turkey	2Y03	2.85	[18]
			6H7J	2.80	[19]
		β_2 -AR, human	7DHR	3.80	[24]

Table 1 (Cont.)





β -AR agonist	Structure	β -AR, organism	PDB ID	Resolution, Å	References
Noradrenaline		β_1 -AR, human	7BU6	2.70	[21]
Salbutamol		β_1 -AR, turkey	6H7M	2.76	[19]
			2Y04	3.05	[18]
		β_2 -AR, human	7DHI	3.26	[24]
Salmeterol		β_2 -AR, human	6MXT	2.96	[25]
BI167107(Q27464220)		β_1 -AR, human	7BU7	2.60	[21]
			4LDE	2.79	[20]
		β_2 -AR, human	3P0G 3SN6	3.50 3.20	[26]
			6N48	3.20	[27]

Table 2. β -AR blockers (partial agonists, antagonists, and inverse agonists) that have been co-crystallized with the receptor


β -AR blocker	Structure	β -AR, organism	PDB ID	Resolution, Å	References
Alprenolol		β_2 -AR, human	3NYA	3.16	[29]
			6PS2 6PRZ	2.40 2.80	[30]
			6OBA	3.10	[31]

Table 2 (Cont.)





β -AR blocker	Structure	β -AR, organism	PDB ID	Resolution, Å	References
Bucindolol		β_1 -AR, turkey	4AMI	3.20	[32]
Carazolol		β_1 -AR, human	7BVQ	2.50	[21]
		β_1 -AR, turkey	2YCW	3.00	[33]
		β_2 -AR, human	2R4R 2R4S	3.40	[34]
			2RH1	2.40	[35]
			4GBR	3.99	[36]
			5D5A 5D5B	2.48 3.80	[37]
			5JQH	3.20	[38]
6PS0	3.40	[30]			
Carvedilol		β_1 -AR, turkey	4AMJ	2.30	[32]
		β_2 -AR, human	6PS3	2.50	[30]
Cyanopindolol		β_1 -AR, turkey	2VT4	2.70	[39]
			2YCX 2YCY	3.25 3.15	[33]
			4BVN	2.10	[40]
			5F8U	3.35	[41]
			6H7O	2.80	[19]

Table 2 (Cont.)









β -AR blocker	Structure	β -AR, organism	PDB ID	Resolution, Å	References
Iodocyanopindolol		β_1 -AR, turkey	2YCZ	3.65	[33]
7-Methylcyanopindolol		β_1 -AR, turkey	5A8E	2.40	[42]
Propranolol		β_2 -AR, human	6PS5	2.90	[30]
Timolol		β_2 -AR, human	3D4S	2.80	[43]
			6PS1 6PS6	3.20 2.70	[30]
Xamoterol		β_1 -AR, turkey	6H7N	2.50	[19]

Table 2 (Cont.)

β -AR blocker	Structure	β -AR, organism	PDB ID	Resolution, Å	References
ICI-118,551		β_2 -AR, human	3NY8	2.84	[29]
			6PS4	2.60	[30]
Q27460040		β_2 -AR, human	3PDS	3.50	[44]
Q27461782		β_2 -AR, human	3NY9	2.84	[29]

and 7 (Fig. 1). Multiple biochemical and mutagenesis studies, as well as analysis of crystal structures of aminergic GPCRs, have allowed to locate critical amino acid residues in the TM helices [45]. It was demonstrated that the charged amine of the ligand interacts with Asp residue D3.32. GPCRs with D3.32 also have a Tyr residue at position Y7.43 and contain Asn at position N7.39, which suggests that their side chains are involved in the interactions with the positively charged moieties in the ligands. There-

fore, these key amino acids form the center for the binding of amino groups and other polar groups of the ligand tail.

In the second center of polar interactions, all catecholamine receptors have Ser residues at positions S5.42 and S5.46; most of them also have Ser at position S5.43, so that these residues can form H-bonds with the donors and/or acceptors of the aromatic head. Recent data [10] indicate that Thr at position T3.37 also can interact with polar groups of the ligand head.

Figure 2 shows the alignment of amino acid sequences of TM helices 3, 5, 6, and 7 in β -AR subtypes β_1 , β_2 , and β_3 from different animal species. All key amino acid residues mentioned above are highly conserved in all β -ARs.

Comparison of conformations of agonists, antagonists, and inverse agonists bound to β -ARs. Figure 3 shows crystal structures of the agonist isoprenaline (panel a) and neutral antagonist cyanopindolol (panel b) bound in the

main binding pocket of β_1 -Ars [18, 33]. The figure shows the side chains of the amino acid residues forming the two centers of polar interactions as well as ligand conformations. As seen in Fig. 3b, the O-C-C-C group of atoms in cyanopindolol tail acquires a *gauche*-conformation (i.e., forms a kink in the tail), while the C-C-C-N group of atoms in the isoprenaline tail has a *trans*-conformation (Fig. 3a).

Figure 4 shows the superimposed structures from Fig. 3. It is clearly seen that the O-C-C-C group of atoms forms a kink in the cyanopindolol tail, and the isoprenaline tail has an extended conformation. Analysis shows that the same picture is observed in other complexes of agonists and antagonists with the receptors (Tables 1 and 2).

The amine groups of both ligands are located in the amine-binding center (D3.32, N7.39, Y7.43), while catechol hydroxyls of isoprenaline and NH- and cyanogroups of cyanopindolol are situated in the other center of polar interactions (S5.42, S5.43, S5.46). However, the overall geometries of the agonist and antagonist molecules are different. In isoprenaline, the tail has an extended (*trans*-) conformation, and the molecule resembles a “strained string” that stabilizes the active state of the receptor. The tail of cyanopindolol is bent between the amine N-atom and the aromatic ring, resulting in the zigzag-like conformation (Figs. 3 and 4). Under other conditions (for example, in a native membrane, and not in a crystal), the tail of the antagonist can be transformed into an extended conformation and back, i.e., TM helices in the receptor complexes with antagonists can have a greater dynamic mobility than in the complexes with agonists (see Nygaard et al. (2013) [6]).




Fig. 1. Typical structure of the agonist complex with TM helices 3, 5, 6, and 7 forming the binding site in β -ARs. The key amino acid residues interacting with the ligand are shown as circles.

	TM3		TM5		TM6		TM7					
	D3.32	T3.37	S5.42	S5.43	S5.46	W6.48	P6.50	F6.51	F6.52	N7.39	Y7.43	N7.49
SP P08580 ADRB1_HUMAN	LWTSVDVLCVTSASIEITLCVIAL	133-154	AYAIASSVVSFYPLLCIMAFVYLRVF	223-240	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	320-349	PDRLVFFVFNWLGYSANSAFNPIIY	355-377				
SP P47899 ADRB1_MACMU	LWTSVDVLCVTSASIEITLCVIAL	133-154	AYAIASSVVSFYPLLCIMAFVYLRVF	223-240	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	323-352	PDRLVFFVFNWLGYSANSAFNPIIY	358-380				
SP Q97196 ADRB1_BOVIN	LWTSVDVLCVTSASIEITLCVIAL	133-154	GYAITSSVVSFYPLLCIMAFVYLRVF	223-248	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	307-336	PDRLVFFVFNWLGYSANSAFNPIIY	342-364				
SP Q28998 ADRB1_PIG	LWTSVDVLCVTSASIEITLCVIAL	133-154	AYAIASSVVSFYPLLCIMAFVYLRVF	222-247	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	310-339	PDRLVFFVFNWLGYSANSAFNPIIY	345-367				
SP Q28927 ADRB1_SHEEP	LWTSVDVLCVTSASIEITLCVIAL	133-154	GYAITSSVVSFYPLLCIMAFVYLRVF	223-248	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	307-336	PDRLVFFVFNWLGYSANSAFNPIIY	342-364				
SP P79149 ADRB1_CANLF	LWTSVDVLCVTSASIEITLCVIAL	133-154	AYAIASSVVSFYPLLCIMAFVYLRVF	223-248	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	317-346	PDRLVFFVFNWLGYSANSAFNPIIY	352-374				
SP Q97576 ADRB1_FELCA	LWTSVDVLCVTSASIEITLCVIAL	133-154	AYAIASSVVSFYPLLCIMAFVYLRVF	223-248	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	316-345	PDRLVFFVFNWLGYSANSAFNPIIY	351-373				
SP P07700 ADRB1_MELGA	CWTSIDVLCVTSASIEITLCVIAI	116-137	AYAIASSVVSFYPLLCIMAFVYLRVF	206-231	HKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	286-315	PDRLVFFVFNWLGYSANSAFNPIIY	321-343				
SP P18090 ADRB1_RAT	LWTSVDVLCVTSASIEITLCVIAL	133-154	AYAIASSVVSFYPLLCIMAFVYLRVF	223-248	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	309-338	PDRLVFFVFNWLGYSANSAFNPIIY	344-366				
SP P34971 ADRB1_MOUSE	LWTSVDVLCVTSASIEITLCVIAL	133-154	AYAIASSVVSFYPLLCIMAFVYLRVF	223-248	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	309-338	PDRLVFFVFNWLGYSANSAFNPIIY	344-366				
SP Q42574 ADRB1_XENLA	FWTSVDVLCVTSASIEITLCVIST	110-131	AYAIASSVVSFYPLLCIMAFVYLRVF	201-226	QKALKTLGIIIMGVFTLCWLPPEFLANVVKAF	268-297	PDRLVFFVFNWLGYSANSAFNPIIY	303-325				
SP P07550 ADRB2_HUMAN	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QAYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP Q28509 ADRB2_MACMU	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QAYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP Q28044 ADRB2_BOVIN	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EYVILLNWLGVNSGFNPLIYCRS	306-329				
SP Q28997 ADRB2_PIG	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP P54033 ADRB2_CANLF	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP Q97575 ADRB2_FELCA	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP Q8K424 ADRB2_CAVPO	FWTSIDVLCVTSASIEITLCVIA	108-128	AYAIASSVVSFYPLVVMVVFVYS	198-218	LGIMGTFTLCWLPPEFLANVVKAF	275-295	VYVILLNWLGVNSGFNPLIYCRS	307-327				
SP P04274 ADRB2_MESAU	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP P10608 ADRB2_RAT	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP P18762 ADRB2_MOUSE	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP Q70431 ADRB2_MERUN	EFWTSIDVLCVTSASIEITLCVIAV	33-55	QAYAIASSVVSFYPLVVMVVFVYS	123-146	LGIMGTFTLCWLPPEFLANVVKAF	201-224	EVYILLNWLGVNSGFNPLIYCRS	232-251				
SP Q9KWL2 ADRB2_TSCTR	EFWTSIDVLCVTSASIEITLCVIAV	107-129	QAYAIASSVVSFYPLVVMVVFVYS	197-220	LGIMGTFTLCWLPPEFLANVVKAF	275-298	EVYILLNWLGVNSGFNPLIYCRS	306-329				
SP Q8U0V9 ADRB2_ONCMY	EFWTSIDVLCVTSASIEITLCVIAL	110-132	AYAIASSVVSFYPLVVMVVFVYS	200-223	LGIMGTFTLCWLPPEFLANVVKAF	283-306	EVYILLNWLGVNSGFNPLIYCRS	319-337				
SP P13945 ADRB3_HUMAN	LWTSVDVLCVTSASIEITLCALAV	112-133	YVLLSSVVSFYPLVVMVVFVYS	204-225	TGLIMGTFTLCWLPPEFLANVVKAF	293-314	VFVILLNWLGVNSGFNPLIYCRS	327-347				
SP Q28524 ADRB3_MACMU	LWTSVDVLCVTSASIEITLCALAV	112-133	YVLLSSVVSFYPLVVMVVFVYS	204-225	TGLIMGTFTLCWLPPEFLANVVKAF	293-314	VFVILLNWLGVNSGFNPLIYCRS	327-347				
SP P46626 ADRB3_BOVIN	LWTSVDVLCVTSASIEITLCALAV	112-133	YVLLSSVVSFYPLVVMVVFVYS	204-225	TGLIMGTFTLCWLPPEFLANVVKAF	293-314	VFVILLNWLGVNSGFNPLIYCRS	327-347				
SP Q95252 ADRB3_PIG	LWTSVDVLCVTSASIEITLCALAV	112-133	YVLLSSVVSFYPLVVMVVFVYS	204-225	TGLIMGTFTLCWLPPEFLANVVKAF	293-314	VFVILLNWLGVNSGFNPLIYCRS	327-347				
SP Q9X758 ADRB3_SHEEP	LWTSVDVLCVTSASIEITLCALAV	112-133	YVLLSSVVSFYPLVVMVVFVYS	204-225	TGLIMGTFTLCWLPPEFLANVVKAF	293-314	VFVILLNWLGVNSGFNPLIYCRS	327-347				
SP Q9X757 ADRB3_CAPHI	LWTSVDVLCVTSASIEITLCALAV	112-133	YVLLSSVVSFYPLVVMVVFVYS	204-225	TGLIMGTFTLCWLPPEFLANVVKAF	293-314	VFVILLNWLGVNSGFNPLIYCRS	327-347				
SP Q20622 ADRB3_CANLF	LWTSVDVLCVTSASIEITLCALAV	112-133	YVLLSSVVSFYPLVVMVVFVYS	204-225	TGLIMGTFTLCWLPPEFLANVVKAF	293-314	VFVILLNWLGVNSGFNPLIYCRS	327-347				
SP Q97574 ADRB3_FELCA	ELWTSVDVLCVTSASIEITLCALAV	111-133	IPYVLLSSVVSFYPLVVMVVFVYS	202-225	TGLIMGTFTLCWLPPEFLANVVKAF	294-317	VFVILLNWLGVNSGFNPLIYCRS	326-349				
SP Q20483 ADRB3_CAVPO	LWTSVDVLCVTSASIEITLCALAV	109-130	YVLLSSVVSFYPLVVMVVFVYS	201-222	TGLIMGTFTLCWLPPEFLANVVKAF	291-312	VFVILLNWLGVNSGFNPLIYCRS	325-345				
SP P26255 ADRB3_RAT	LWTSVDVLCVTSASIEITLCALAV	109-130	YVLLSSVVSFYPLVVMVVFVYS	201-222	TGLIMGTFTLCWLPPEFLANVVKAF	290-311	VFVILLNWLGVNSGFNPLIYCRS	324-344				
SP P25962 ADRB3_MOUSE	LWTSVDVLCVTSASIEITLCALAV	109-130	YVLLSSVVSFYPLVVMVVFVYS	201-222	TGLIMGTFTLCWLPPEFLANVVKAF	290-311	VFVILLNWLGVNSGFNPLIYCRS	324-344				

Fig. 2. Multiple sequence alignment of TM3, TM5, TM6, and TM7 domains of β -ARs for different animal species. Domain information and protein sequences were taken from Swiss-Prot UniProt Knowledgebase (35 proteins) [14]. Key amino acids in the sequences are shown with a gray background.




Fig. 3. The main binding pocket of the β_1 -AR with (a) agonist (isoprenaline; PDB ID, 2Y03) and (b) antagonist (cyanopindolol; PDB ID, 2YCY). Images are generated using PyMOL Molecular Graphics System.




Fig. 4. Comparison of structures of the agonist (isoprenaline, orange) and antagonist (cyanopindolol, dark cyan) complexes with β_1 -AR (PDB ID, 2Y03, yellow, and 2YCY, blue). a) View from the receptor extracellular side; important residues are labeled according to Ballesteros–Weinstein notation [17]; b) overview of bound ligand conformation. The images are generated using PyMOL Molecular Graphics System.

We have examined other agonists bound to the corresponding aminergic GPCRs and, indeed, the tail fragment between the amine N-atom and the aromatic ring in these complexes also has an extended conformation (PDB ID: 2Y00, 2Y02, 2Y04, 3P0G, 3PDS, 3SN6, and other structures presented in Table 1). On the other hand, antagonist molecules are bent in the tail fragments between the amine N-atom and the aromatic ring (PDB ID: 2VT4, 2YCW, 2RH1, 3D4S, 3NY8, 3NY9, 3NYA, 3PBL, 3RZE, and other structures presented in Table 2). These data suggest that the extended conformation of the agonist tail is of particular importance in the active state stabilization in β -ARs and other aminergic GPCRs. We can

also speculate that the distance between the two centers of polar interactions with the agonists should be equal (or close) to the distance between the corresponding centers in the activated GPCR.

The role of the agonist “strained string” conformation in the β -AR activation. Simple geometry considerations outlined above suggest that the agonist molecule can act as a “strained string” that stabilizes the arrangement of TM helices 3, 5, 6, and 7 corresponding to the receptor active state (Fig. 1). It appears that the interaction with the agonist bring the TM5 helix closer to the TM3 and TM7 helices. In particular, this “strained string” interacts with Trp at position W6.48 and Phe residues at positions F6.51

and F6.52. These interactions are likely to be responsible for the rearrangement of TM6, i.e., for its rotation and/or vertical see-saw movement around a pivot in the middle of the membrane, which results in the opening of the intracellular portion for the G protein binding [46-48]. The interactions with W6.48 result in a subtle rotation of TM6 in the extracellular portion, which is amplified towards the cytoplasmic side by the characteristic kink in the helix introduced by Pro residue P6.50 [11]. Unlike an agonist, an antagonist or an inverse agonist has a longer tail fragments with a loose conformation, a kink in the middle of the tail, and weak polar interactions of the head with the TM5 helix. Therefore, they cannot act as a “strained string”, but instead occupy the active site of the receptor due to the polar and hydrophobic interactions.

Based on these findings, we propose several predictions on how minor differences in the ligand structure can influence its functional characteristics:

1. Elongation of the agonist tail between the amine N-atom and the aromatic ring could result in the agonist conversion into antagonist.

2. Shortening of the tail fragment in the antagonist or inverse agonist with polar moieties in the corresponding positions of their heads may result in their transformation into agonists or partial agonists.

3. Removal of catechol hydroxyls or the corresponding polar substitutes in other aromatic heads could reduce the agonist activity. Modifications of these polar substitutes with aromatic or aliphatic groups substitutes, especially bulky ones, are likely to have a similar effect.

4. Modification of amine groups of ligands (both agonists and antagonists) with bulky substitutes reduce or even prevent ligand binding to GPCRs.

5. The *trans*-conformation (extended conformation) of the agonist tail can be transformed into a *gauche*- or *cis*-conformation by chemical modification, which can result in the reduction of agonist activity or even transform it into an antagonist.

Funding. This work was supported by the Russian Foundation for Basic Research (project no. 20-04-00453).

Ethics declarations. The authors declare no conflicts of interest. This article does not contain descriptions of studies involving humans or animals as study subjects.

Open access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended

use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

REFERENCES

1. Drews, J. (2000) Drug discovery: a historical perspective, *Science*, **287**, 1960-1964, doi: 10.1126/science.287.5460.1960.
2. Eiger, D. S., Pham, U., Gardner, J., Hicks, C., and Rajagopal, S. (2022) GPCR systems pharmacology: a different perspective on the development of biased therapeutics, *Am. J. Physiol. Cell. Physiol.*, **322**, 887-895, doi: 10.1152/ajpcell.00449.2021.
3. Costanzi, S., Siegel, J., Tikhonova, I. G., and Jacobson, K. A. (2009) Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors, *Curr. Pharm. Des.*, **15**, 3994-4002, doi: 10.2174/138161209789824795.
4. Kahsai, A. W., Xiao, K., Rajagopal, S., Ahn, S., Shukla, A. K., et al. (2011) Multiple ligand-specific conformations of the β_2 -adrenergic receptor, *Nat. Chem. Biol.*, **7**, 692-700, doi: 10.1038/nchembio.634.
5. Katritch, V., Cherezov, V., and Stevens, R. C. (2012) Diversity and modularity of G protein-coupled receptor structures, *Trends Pharmacol. Sci.*, **33**, 17-27, doi: 10.1016/j.tips.2011.09.003.
6. Nygaard, R., Zou, Y., Dror, R. O., Mildorf, T. J., Arlow, D. H., et al. (2013) The dynamic process of β_2 -adrenergic receptor activation, *Cell*, **152**, 532-542, doi: 10.1016/j.cell.2013.01.008.
7. Weis, W. I., and Kobilka, B. K. (2018) The molecular basis of G protein-coupled receptor activation, *Annu. Rev. Biochem.*, **87**, 897-919, doi: 10.1146/annurev-biochem-060614-033910.
8. Frei, J. N., Broadhurst, R. W., Bostock, M. J., Solt, A., Jones, A. J. Y., et al. (2020) Conformational plasticity of ligand-bound and ternary GPCR complexes studied by ^{19}F NMR of the β_1 -adrenergic receptor, *Nat. Commun.*, **11**, 669, doi: 10.1038/s41467-020-14526-3.
9. Lebon, G., Warne, T., and Tate, C. G. (2012) Agonist-bound structures of G protein-coupled receptors, *Curr. Opin. Struct. Biol.*, **22**, 482-490, doi: 10.1016/j.sbi.2012.03.007.
10. Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., et al. (2013) Structural basis for molecular recognition at serotonin receptors, *Science*, **340**, 610-614, doi: 10.1126/science.1232807.
11. Standfuss, J., Edwards, P. C., D’Antona, A., Fransen, M., Xie, G., et al. (2011) The structural basis of agonist-induced activation in constitutively active rhodopsin, *Nature*, **471**, 656-660, doi: 10.1038/nature09795.
12. Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F., et al. (2013) Molecular signatures

- of G-protein-coupled receptors, *Nature*, **494**, 185-194, doi: 10.1038/nature11896.
13. Granier, S., and Kobilka, B. (2012) A new era of GPCR structural and chemical biology, *Nat. Chem. Biol.*, **8**, 670-673, doi: 10.1038/nchembio.1025.
 14. The UniProt Consortium (2021) UniProt: the universal protein knowledgebase in 2021, *Nucleic Acids Res.*, **49**, D480-D489, doi: 10.1093/nar/gkaa1100.
 15. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., et al. (2000) The protein data bank, *Nucleic Acids Res.*, **28**, 235-242, doi: 10.1093/nar/28.1.235.
 16. Sayle, R. A., and Milner-White, E. J. (1995) RASMOL: biomolecular graphics for all, *Trends Biochem. Sci.*, **20**, 374, doi: 10.1016/s0968-0004(00)89080-5.
 17. Ballesteros, J. A., and Weinstein, H. (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors, in *Methods in Neurosciences* (Sealfon, S. C., ed.) Academic Press, USA, pp. 366-428, doi: 10.1016/S1043-9471(05)80049-7.
 18. Warne, T., Moukhametzianov, R., Baker, J. G., Nehmé, R., Edwards, P. C., et al. (2011) The structural basis for agonist and partial agonist action on a β_1 -adrenergic receptor, *Nature*, **469**, 241-244, doi: 10.1038/nature09746.
 19. Warne, T., Edwards, P. C., Doré, A. S., Leslie, A. G. W., and Tate, C. G. (2019) Molecular basis for high-affinity agonist binding in GPCRs, *Science*, **364**, 775-778, doi: 10.1126/science.aau5595.
 20. Ring, A. M., Manglik, A., Kruse, A. C., Enos, M. D., Weis, W. I., et al. (2013) Adrenaline-activated structure of β_2 -adrenoceptor stabilized by an engineered nanobody, *Nature*, **502**, 575-579, doi: 10.1038/nature12572.
 21. Xu, X., Kaindl, J., Clark, M. J., Hübner, H., Hirata, K., et al. (2021) Binding pathway determines norepinephrine selectivity for the human β_1 AR over β_2 AR, *Cell Res.*, **31**, 569-579, doi: 10.1038/s41422-020-00424-2.
 22. Lee, Y., Warne, T., Nehmé, R., Pandey, S., Dwivedi-Agnihotri, H., et al. (2020) Molecular basis of β -arrestin coupling to formoterol-bound β_1 -adrenoceptor, *Nature*, **583**, 862-866, doi: 10.1038/s41586-020-2419-1.
 23. Zhang, Y., Yang, F., Ling, S., Lv, P., Zhou, Y., et al. (2020) Single-particle cryo-EM structural studies of the β_2 AR-Gs complex bound with a full agonist formoterol, *Cell Discov.*, **6**, 4, doi: 10.1038/s41421-020-0176-9.
 24. Yang, F., Ling, S. L., Zhou, Y. X., Zhang, Y. N., Lv, P., et al. (2021) Different conformational responses of the beta2-adrenergic receptor-Gs complex upon binding of the partial agonist salbutamol or the full agonist isoprenaline, *Natl. Sci. Rev.*, **8**, nwaa284, doi: 10.1093/nsr/nwaa284.
 25. Masureel, M., Zou, Y., Picard, L. P., Van der Westhuizen, E., Mahoney, J. P., et al. (2018) Structural insights into binding specificity, efficacy and bias of a β_2 AR partial agonist, *Nat. Chem. Biol.*, **14**, 1059-1066, doi: 10.1038/s41589-018-0145-x.
 26. Rasmussen, S. G., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., et al. (2011) Crystal structure of the β_2 adrenergic receptor-Gs protein complex, *Nature*, **477**, 549-555, doi: 10.1038/nature10361.
 27. Liu, X., Masoudi, A., Kahsai, A. W., Huang, L. Y., Pani, B., et al. (2019) Mechanism of β_2 AR regulation by an intracellular positive allosteric modulator, *Science*, **364**, 1283-1287, doi: 10.1126/science.aaw8981.
 28. Emtage, A. L., Mistry, S. N., Fischer, P. M., Kellam, B., and Laughton, C. A. (2017) GPCRs through the keyhole: the role of protein flexibility in ligand binding to β -adrenoceptors, *J. Biomol. Struct. Dyn.*, **35**, 2604-2619, doi: 10.1080/07391102.2016.1226197.
 29. Wacker, D., Fenalti, G., Brown, M. A., Katritch, V., Abagyan, R., et al. (2010) Conserved binding mode of human β_2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography, *J. Am. Chem. Soc.*, **132**, 11443-11445, doi: 10.1021/ja105108q.
 30. Ishchenko, A., Stauch, B., Han, G. W., Batyuk, A., Shiriaeva, A., et al. (2019) Toward G protein-coupled receptor structure-based drug design using X-ray lasers, *IUCrJ*, **24** (Pt 6), 1106-1119, doi: 10.1107/S2052252519013137.
 31. Liu, X., Kaindl, J., Korczynska, M., Stöbel, A., Dengler, D., Stanek, M., et al. (2020) An allosteric modulator binds to a conformational hub in the β_2 adrenergic receptor, *Nat. Chem. Biol.*, **16**, 749-755, doi: 10.1038/s41589-020-0549-2.
 32. Warne, T., Edwards, P. C., Leslie, A. G., and Tate, C. G. (2012) Crystal structures of a stabilized β_1 -adrenoceptor bound to the biased agonists bucindolol and carvedilol, *Structure*, **20**, 841-849, doi: 10.1016/j.str.2012.03.014.
 33. Moukhametzianov, R., Warne, T., Edwards, P. C., Serrano-Vega, M. J., Leslie, A. G., et al. (2011) Two distinct conformations of helix 6 observed in antagonist-bound structures of a β_1 -adrenergic receptor, *Proc. Natl. Acad. Sci. USA*, **108**, 8228-8232, doi: 10.1073/pnas.1100185108.
 34. Rasmussen, S. G., Choi, H. J., Rosenbaum, D. M., Kobilka, T. S., Thian, F. S., et al. (2007) Crystal structure of the human β_2 adrenergic G-protein-coupled receptor, *Nature*, **450**, 383-387, doi: 10.1038/nature06325.
 35. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., et al. (2007) High-resolution crystal structure of an engineered human β_2 -adrenergic G protein-coupled receptor, *Science*, **23**, 1258-1265, doi: 10.1126/science.1150577.
 36. Zou, Y., Weis, W. I., and Kobilka, B. K. (2012) N-terminal T4 lysozyme fusion facilitates crystallization of a G protein coupled receptor, *PLoS One*, **7**, e46039, doi: 10.1371/journal.pone.0046039.
 37. Huang, C. Y., Olieric, V., Ma, P., Howe, N., Vogeley, L., et al. (2016) In meso *in situ* serial X-ray crystallography of soluble and membrane proteins at cryogenic temperatures, *Acta Crystallogr. D Struct. Biol.*, **72** (Pt 1), 93-112, doi: 10.1107/S2059798315021683.
 38. Staus, D. P., Strachan, R. T., Manglik, A., Pani, B., Kahsai, A. W., et al. (2016) Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation, *Nature*, **535**, 448-452, doi: 10.1038/nature18636.

39. Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhamet-zianov, R., Edwards, P. C., et al. (2008) Structure of a β_1 -adrenergic G-protein-coupled receptor, *Nature*, **454**, 486-491, doi: 10.1038/nature07101.
40. Miller-Gallacher, J. L., Nehmé, R., Warne, T., Edwards, P. C., Schertler, G. F., et al. (2014) The 2.1 Å resolution structure of cyanopindolol-bound β_1 -adrenoceptor identifies an intramembrane Na^+ ion that stabilises the ligand-free receptor, *PLoS One*, **9**, e92727, doi: 10.1371/journal.pone.0092727.
41. Leslie, A. G., Warne, T., and Tate, C. G. (2015) Ligand occupancy in crystal structure of β_1 -adrenergic G protein-coupled receptor, *Nat. Struct. Mol. Biol.*, **22**, 941-942, doi: 10.1038/nsmb.3130.
42. Sato, T., Baker, J., Warne, T., Brown, G. A., Leslie, A. G., et al. (2015) Pharmacological analysis and structure determination of 7-methylcyanopindolol-bound β_1 -adrenergic receptor, *Mol. Pharmacol.*, **88**, 1024-1034, doi: 10.1124/mol.115.101030.
43. Hanson, M. A., Cherezov, V., Griffith, M. T., Roth, C. B., Jaakola, V. P., et al. (2008) A specific cholesterol binding site is established by the 2.8 Å structure of the human β_2 -adrenergic receptor, *Structure*, **16**, 897-905, doi: 10.1016/j.str.2008.05.001.
44. Rosenbaum, D. M., Zhang, C., Lyons, J. A., Holl, R., Aragao, D., et al. (2011) Structure and function of an irreversible agonist- β_2 adrenoceptor complex, *Nature*, **469**, 236-240, doi: 10.1038/nature09665.
45. Conner, A. C., Barwell, J., Poyner, D. R., and Wheatley, M. (2011) The use of site-directed mutagenesis to study GPCRs, *Methods Mol. Biol.*, **746**, 85-98, doi: 10.1007/978-1-61779-126-0_5.
46. Rasmussen, S. G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., et al. (2011) Structure of a nanobody-stabilized active state of the β_2 adrenoceptor, *Nature*, **469**, 175-180, doi: 10.1038/nature09648.
47. Chung, K. Y. (2013) Structural aspects of GPCR-G protein coupling, *Toxicol. Res.*, **29**, 149-155, doi: 10.5487/TR.2013.29.3.149.
48. Wu, Y., Zeng, L., and Zhao, S. (2021) Ligands of adrenergic receptors: a structural point of view, *Biomolecules*, **11**, 936, doi: 10.3390/biom11070936.